CERVOMED INC. news, videos and press releases
For more news please use our advanced search feature.
CERVOMED INC. - More news...
CERVOMED INC. - More news...
- Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
- CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
- CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
- CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
- CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
- CervoMed to Present at the 8th International Lewy Body Dementia Conference
- CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
- CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
- CervoMed Announces Key Senior Leadership Appointments
- CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
- CervoMed to Participate in Upcoming Investor Conferences
- CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
- CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
- CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
- CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
- CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
- CervoMed to Participate in Upcoming Investor Conferences
- CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
- CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
- CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
- CervoMed to Participate in the Emerging Growth Conference
- CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
- CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
- CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
- CervoMed to Appoint William Elder as Chief Financial Officer
- CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
